Clinical Core B

项目概要/摘要 核心B（临床核心），这个NIA U19中心在宾夕法尼亚大学（Penn）佩雷尔曼学院， 医学将是至关重要的，以实现所有项目的目标和其他核心的多学科 研究计划。宾夕法尼亚大学U19中心专注于解决阿尔茨海默病（AD）的优先事项， 相关性痴呆（ADRD），多病因痴呆的主题领域，如路易体（LB）障碍 (LBD)包括路易体痴呆（DLB）和帕金森病（PD）痴呆（PDD）。之间 ADRD是AD中最常见的亚型，AD与丰富的LB共病。因此，AD与LB和Lewy 神经突（LN）α-突触核蛋白（aSyn）病理（AD+aSyn）、PDD和DLB一起代表了最常见的 常见的老年痴呆症这个新的宾夕法尼亚州ADRD U19中心的总体目标是 阐明AD+aSyn与纯aSyn中病理性aSyn介导的进行性神经变性的机制 AD（AD-aSyn），并与LBD进行比较，作为老化和非均质积累的函数， aSyn、tau和淀粉样蛋白β（Aβ）病理影响这些疾病的不同和可变的临床表现， 紊乱核心B的目标是：（1）招募、评估和留住具有LBD的U19研究参与者 项目I-IV;（2）与核心C合作，从现有和新的生物标志物/生物流体和组织收集 核心B LBD参与者，并在死前尽可能长时间对其进行纵向评估，以优化 临床病理相关性;（3）与核心A合作，教育医学界和一般 公众对LBD和相关疾病，并培养下一代PD临床和翻译 研究人员;（4）与核心D合作，为宾夕法尼亚大学提供高质量的临床和生物标志物数据 整合神经退行性疾病数据库（INDD），促进临床和生物标志物数据的共享 在宾夕法尼亚大学内外与新的和长期的内部，国家和国际合作者。

Project Summary / Abstract Core B (Clinical Core) of this NIA U19 Center at the University of Pennsylvania (Penn) Perelman School of Medicine will be crucial to accomplishing the goals of all Projects and other Cores of this multidisciplinary research program. The Penn U19 Center focuses on priorities that address Alzheimer's disease (AD) and related dementias (ADRD) in topic areas of multiple etiology dementias, such as Lewy body (LB) disorders (LBD), including dementia with Lewy bodies (DLB) and Parkinson's disease (PD) dementia (PDD). Among ADRD, AD with abundant LB co-pathology is the most common subtype of AD. Hence, AD with LB and Lewy neurite (LN) alpha-synuclein (aSyn) pathologies (AD+aSyn), PDD and DLB together represent the most common forms of aging-related dementias. The overall goals of this new Penn ADRD U19 Center are to elucidate mechanisms of pathological aSyn-mediated progressive neurodegeneration in AD+aSyn versus pure AD (AD-aSyn), and also compared with LBD, as a function of aging and the heterogeneous accumulations of aSyn, tau and amyloid β (Aβ) pathologies that influence different and variable clinical manifestations of these disorders. The aims for Core B are to: (1) recruit, assess and retain research participants with LBD for U19 Projects I-IV; (2) collaborate with Core C for biomarker/biofluid and tissue collection from existing and new Core B LBD participants, and to assess them longitudinally antemortem for as long as possible to optimize clinical-pathological correlations; (3) collaborate with Core A to educate the medical community and general public on LBD and related disorders, and to train the next generation of PD clinical and translational researchers; and (4) collaborate with Core D to contribute high-quality clinical and biomarker data to the Penn Integrated NeuroDegenerative Disease Database (INDD) and facilitate sharing of clinical and biomarker data within and outside of Penn with new and longstanding internal, national and international collaborators.